Hillhurst Biopharmaceuticals, Inc.

Unlocking the potential of therapeutic gasses through novel liquid medicines

Add To Watchlist
General Information
Company Name
Hillhurst Biopharmaceuticals, Inc.
Founded Year
2012
Location (Offices)
+1
Founders / Decision Makers
Alonso Guzmán - Consultant: Regulatory Affairs and Operations, US Submission Management
Number of Employees
10
Industries
Biotechnology, Health and Wellness, Life Sciences +2
Funding Stage
Seed
Social Media

Hillhurst Biopharmaceuticals, Inc. - Company Profile

is a pioneering biotech company with a vision to unleash the potential of therapeutic gases via innovative liquid medicines. Leveraging its proprietary GLASS platform, the company is breaking new ground in the application of therapeutic gases, traditionally limited to inhalation delivery. Its distinctive pipeline comprises novel liquid therapeutic candidates targeting conditions such as sickle cell disease, Parkinson’s disease, and acute pain. Founded in 2012, Hillhurst operates at the intersection of Biotechnology, Health and Wellness, Life Sciences, Manufacturing, and Pharmaceutical industries. The company recently secured a significant boost from a Seed Round investment on 20 December 2023, led by Friedman BioVentures. This investment not only heralds potential growth for Hillhurst but also underscores confidence from established players in the biotech investment landscape.

Taxonomy: therapeutic gases, GLASS platform, liquid medicines, sickle cell disease, Parkinson's disease, acute pain, carbon monoxide therapy, cellular metabolic system, heme oxygenase, inflammatory processes, cell death prevention, hemoglobin polymerization, novel liquid therapeutics, dosing technology, pharmaceutical innovation

Funding Rounds & Investors of Hillhurst Biopharmaceuticals, Inc. (3)

View All
Funding Stage Amount No. Investors Investors Date
Seed Round Unknown 1 Friedman BioVentures 20 Dec 2023
Grant $2.00M 1 National Institutes of Health 07 Nov 2023
Grant $3.00M 1
National Heart, Lung and Blood Institute, investor in Hillhurst Biopharmaceuticals, Inc.'s Grant round
20 Sep 2023

Latest News of Hillhurst Biopharmaceuticals, Inc.

View All

No recent news or press coverage available for Hillhurst Biopharmaceuticals, Inc..

Similar Companies to Hillhurst Biopharmaceuticals, Inc.

View All
Spur Therapeutics - Similar company to Hillhurst Biopharmaceuticals, Inc.
Spur Therapeutics Toward the next generation of gene therapy.
MedBiome - Similar company to Hillhurst Biopharmaceuticals, Inc.
MedBiome Targeting the microbiome to improve human health
Alzamend Neuro - Similar company to Hillhurst Biopharmaceuticals, Inc.
Alzamend Neuro Targeting treatment for Alzheimer's Disease, Major Depressive Disorder, Bipolar Disorder, and PTSD.
Anocca - Similar company to Hillhurst Biopharmaceuticals, Inc.
Anocca Engineered Immunity
Cantabio Pharmaceuticals, Inc. - Similar company to Hillhurst Biopharmaceuticals, Inc.
Cantabio Pharmaceuticals, Inc. Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.
Circle Decoration Circle Decoration

Want to dive deeper into Hillhurst Biopharmaceuticals, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now